Structure Therapeutics is a biotechnology company that develops innovative medicines using advanced computing and structure-based technologies. The company focuses on creating oral small molecule drugs that aim to deliver biologic-like activity and specificity while overcoming limitations of biologic and peptide drugs.

Structure Therapeutics

Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.

Piper Heartland Healthcare Capital

Deep Track Capital

Biotechnology Value Fund

Casdin Capital

Woodline Partners

Lilly Asia Ventures

Sage Partners

Surveyor Capital

TCG Crossover

TF Capital

Cormorant Asset Management

Eight Roads Ventures

Next month, our team will participate in fireside chats at both the Morgan Stanley 22nd Annual Global Healthcare Conference and Cantor Fitzgerald's Global Healthcare Conference 2024. Live and archived webcasts will be accessible from the Events & Presentations page on our website. Replays will be available for 90 days. Read more here: https://lnkd.in/e-rS_Ni2

It takes so little effort to acknowledge someone's contributions, yet its impact can be immeasurable. That’s why we launched our internal global recognition program. Help us in honoring our Structure Salute recipients from last quarter for going above and beyond and living and breathing our values. Congratulations! 👏

At Structure, we take pride in the values that define us. Our collective passion for the work we do and the lives we touch allows us to engage in every opportunity with the energy it deserves. Each of our teams demonstrated their passion for their work during a recent company-wide poster session. This was an invaluable experience for all as we learned how we can best collaborate as a unit to contribute toward our mission of making medicines accessible for all.

Today we announced results from Q2 2024, a pivotal time for our team. Our key progress included the Phase 2a #obesity results demonstrating GSBR-1290 as a potential best-in-class oral small molecule, the continued advancement of our broad oral incretin franchise, and the expansion of our clinical-stage pipeline with the initiation of our LPA1R Phase 1 trial. Read more in today's Q2 earnings announcement here: https://lnkd.in/et77dAbr

❗ IMPORTANT NOTICE FOR JOB SEEKERS ❗ 

It has come to our attention that fraudulent activity has taken place in reference to Structure employees contacting job-seeking candidates regarding potential job opportunities with our firm, and sending offer letters on behalf of our organization. These fraudulent messages sometimes include a request for payment and confidential personal information. Please note that Structure’s recruiting process does not include asking candidates for payments or other highly confidential financial information.

If you are contacted or approached by anyone who is pretending to be employed with Structure in this manner, please report them immediately by sending a message via LinkedIn or contacting us at https://lnkd.in/euCsybM3. We take this matter very seriously and are taking all appropriate measures to address this.

Please find our open roles for consideration and follow the application process on our careers page here: https://lnkd.in/e7rmR-RX

On #NationalInternDay, we’re extending our gratitude to the young, bright interns who have joined us at our San Francisco and Shanghai locations. Over the past couple months, this group has brought a new energy to our team while gaining real-world experience within the #biotech field. It’s been a pleasure working alongside them and sharing our love for the mission we have and the work we do.

For those that face Type 2 #diabetes, there can often be a heavy amount of misconceptions and stereotypes. We are supporting our partners at Beyond Type 2 this week as they fight to end the stigma around Type 2, creating a more honest and understanding narrative. Learn more below.

We had a wonderful time hosting our families for the day at our office and lab space in Shanghai. During our family day, we toured our facilities and showed our loved ones what a day in the #biotech world looks like. We believe in the importance of #STEM education, and our children were especially inspired by the roles scientists play in making a difference for patients living with disease. Following the office tour, we enjoyed a nice dinner with great food and even greater company.

Chronic diseases, including obesity, are rapidly increasing worldwide, escalating the demand for life-changing medicines. At Structure, we are determined to address these devastating #obesity figures with innovative, #smallmolecule medicines without the inherent limitations of peptides and biologics. Oral small molecule drugs can  offer improved patient experience and broad access. Learn more about our platform here: https://lnkd.in/eHpMkXRm

Our internal global recognition program, Structure Impact, recognizes our team members' exceptional work and celebrates those who embody our core values day in and day out. We're excited to introduce you to our Structure Salute recipients each quarter and share their above and beyond employee contributions.

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

news impact assignment basic	general
public peers	general	Aug 31, 2024 12:11 PM	32df17d1
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general
crunchbase profile	general
li profile	general	Aug 31, 2024 12:11 PM	227b9a25
translate crunchbase fundingrounds	general
peers	general	Aug 31, 2024 12:11 PM	602ef323
news basic	general	Aug 31, 2024 12:11 PM	5b79edf1
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

COM:STRUCTURETX

Structure Therapeutics

Last Close

36.97

13/11 21:00

Market Cap

2.25B

Beta: -

Volume Today

339.53K

Avg: -